KOSDAQBiotech & Pharma214450

PharmaResearch

₩267,000▲ 3.49%2026-11-18 close
Market Cap
₩2.8T
Turnover
₩24.8B
Volume
90K
Shares out.
10.4M
PER
16.6×
PBR
—
EPS
₩15,082
Dividend Yield
1.47%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩3,700 per share · Prices as of the 2026-11-18 close

01

Report overview

Rejuran exports push overseas share to 48%

PharmaResearch grew sales and operating profit sharply in 2025, and overseas sales reached about 48% of revenue in the third quarter of 2026. Net profit attributable to controlling shareholders fell year on year in the same quarter, so the profit trend is mixed.

  1. 1

    Revenue for 2025 was KRW 536.3 billion, up 53.2% from the prior year. Operating profit was KRW 214.4 billion, up 70.1%, with an operating margin of 40.0%.

  2. 2

    Third-quarter 2026 revenue was KRW 171.5 billion, up 26.7% year on year, while operating profit of KRW 62.6 billion rose only 1.2%.

  3. 3

    Net profit attributable to controlling shareholders was KRW 30 billion in the same quarter, down 38.8% year on year, moving in a different direction from sales and operating profit.

  4. 4

    Third-quarter 2026 cosmetics exports reached KRW 42.1 billion, up 92%, and medical device exports were about KRW 30 billion, up 53%, according to company figures released on November 6, 2026.

  5. 5

    Selling, general and administrative expenses rose 57.2% to KRW 196.8 billion in 2025, making cost control the next item to watch.

02

Business structure

PharmaResearch develops and sells medical devices, cosmetics and pharmaceuticals based on polynucleotide (PN) material derived from salmon DNA, operating as a regenerative medicine specialist.

Its flagship product Rejuran is an injectable skin booster for facial wrinkle improvement, and the Conjuran joint injection is another key medical device. Medical device sales in 2025 were KRW 314.4 billion, up 62.5% year on year, and cosmetics sales were KRW 131.6 billion, up 69.4%.

The combined share of these two segments rose from 75.2% in 2023 to 83.1% in 2025. Medical device exports in 2025 were KRW 88.6 billion, about 28% of medical device sales.

In Korea, the cosmetics line is sold through Olive Young and Coupang, while overseas it is sold through Sephora and Costco in the United States and through Shopee and TikTok Shop in Southeast Asia.

According to third-quarter preliminary results released on November 6, 2026, cosmetics sales were KRW 62 billion, medical device sales were KRW 87.1 billion (domestic KRW 57.1 billion, exports about KRW 30 billion), and pharmaceutical sales were KRW 19.4 billion.

Medical device exports are widening in Europe through a partnership with the French aesthetics company Laboratoires VIVACY. As of a August 2026 report, Rejuran held overseas product approvals in 52 countries. The company presents more than ten years of accumulated clinical data as the basis of trust in Rejuran.

The structure links domestic treatment demand with overseas exports, and exports accounted for about 48% of third-quarter 2026 sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩135.4B₩61.9B45.7%
2025Q4₩143.3B₩51.9B36.2%
2026Q1₩146.1B₩57.3B39.2%
2026Q2₩178.7B₩66.5B37.2%
2026Q3₩171.5B₩62.6B36.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩194.8B₩65.9B₩40.6B33.8%11.8%28.6%
2023₩261B₩92.3B₩76.6B35.3%17.7%15.8%
2024₩350.1B₩126.1B₩92B36.0%17.1%50.3%
2025₩536.3B₩214.4B₩165.1B40.0%24.0%44.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the basis of disclosed annual results, revenue rose from KRW 194.8 billion in 2022 to KRW 261 billion in 2023 (up 34.0%), KRW 350.1 billion in 2024 (up 34.1%), and KRW 536.3 billion in 2025 (up 53.2%). Revenue has grown for three consecutive years from 2023 through 2025.

Operating profit climbed from KRW 65.9 billion in 2022 to KRW 214.4 billion in 2025, and the operating margin moved from 33.8% in 2022 to 35.3% in 2023, 36.0% in 2024 and 40.0% in 2025. In 2025 operating profit grew 70.1%, faster than revenue, so margin improvement supported earnings growth.

Cost of sales as a share of revenue fell from 28.2% in 2024 to 23.3% in 2025 according to Deal Bio reporting, which points to the cost structure behind the higher margin.

Selling, general and administrative expenses, however, rose 57.2% to KRW 196.8 billion in 2025 from KRW 125.2 billion in 2024, offsetting part of that gain.

Net profit attributable to controlling shareholders grew from KRW 40.6 billion in 2022 to KRW 165.1 billion in 2025, a 79.4% rise in 2025, while net profit including non-controlling interests was KRW 168.3 billion, a different figure.

Operating cash flow reached KRW 183.2 billion in 2025, up from KRW 59.4 billion in 2022. Quarterly revenue peaked at KRW 178.7 billion in the second quarter of 2026, and third-quarter revenue of KRW 171.5 billion fell 4.0% from the prior quarter but rose 26.7% year on year.

Third-quarter operating profit of KRW 62.6 billion declined 5.8% from the prior quarter. Net profit attributable to controlling shareholders fell from KRW 56.6 billion in the second quarter to KRW 30 billion in the third quarter. Over the most recent four quarters, that profit totaled KRW 166.7 billion.

The company said first-half 2026 revenue of KRW 324.8 billion and operating profit of KRW 123.8 billion were record first-half results, in a release dated August 7, 2026.

05

Industry analysis

The market PharmaResearch serves is structured so that skin booster demand such as Rejuran and cosmetics move together with consumption trends at home and abroad.

According to brokerage analysis, foreign-patient dermatology spending hit a record in the second quarter of 2026, and that demand was concentrated among beneficiaries. Analysts also linked growth in skin booster demand to inflows of foreign patients in the first quarter of 2026.

Cosmetics exports are growing through U.S. channels such as Amazon and Sephora alongside online channels in Southeast Asia. The share of medical device exports going to Europe and Oceania rose from 27% in the second quarter of 2025 to 39% in the second quarter of 2026, while Asia's share fell from 70% to 55%.

This indicates sales destinations spreading from an Asia-centered mix toward Europe. In competition, PharmaResearch is compared with listed peers in the same biopharma sector that hold aesthetic medical products, such as Hugel. The company points to clinical data and brand recognition as its differentiators.

From a cycle perspective, overseas approvals and channel expansion are advancing at the same time. Yet as overseas sales grow, exposure to country-specific approval conditions, distribution policy and currency movements also increases. Sector demand is shaped by both foreign visitor flows and domestic consumer conditions.

06

Outlook

On November 6, 2026, the company said it would push into new markets such as South America and the Middle East in the fourth quarter and aim for a record quarterly result.

The medical device segment plans to enter South American markets including Mexico, Argentina and Chile, while the cosmetics segment plans to expand in the Middle East, led by the UAE, and extend channels in Taiwan and Hong Kong.

In its August 7, 2026 release, the company said it would strengthen its business base in Europe and North America in the second half. It plans to build a local base in France to manage European distribution, and to use the recently acquired CG USA production facility to grow its U.S. cosmetics business.

An August 2026 report said brokerage firms projected 2026 revenue of KRW 670 billion. Cumulative revenue for the first three quarters of 2026 was reported as KRW 496.3 billion based on November 6, 2026 disclosures.

Because third-quarter revenue fell from the prior quarter, reaching the annual projection would require a fourth-quarter recovery. In August 2026, brokerages expected sales and profit to keep rising from the prior quarter in the third quarter, but third-quarter revenue actually declined 4.0% from the second quarter.

The key guidance question is how much the new South American and Middle Eastern markets add to fourth-quarter results. The next checkpoint is fourth-quarter 2026 results and the revenue contribution from these new markets.

07

Valuation

PER
16.6×
PBR
—
ROE
23.1%
EPS
₩15,082
BPS
—
Dividend per share
₩3,700

Valuation is best read alongside the earnings trend. Net profit attributable to controlling shareholders over the most recent four quarters totaled KRW 166.7 billion, close to the KRW 165.1 billion recorded for the full year 2025.

That profit rose 79.4% in 2025, but fell 38.8% year on year in the third quarter of 2026, so quarterly earnings have been volatile. Market capitalization sits in a range with a large premium over net assets attributable to controlling shareholders, which stood at KRW 689.3 billion at the end of 2025.

Total equity was KRW 723.9 billion and total liabilities were KRW 320 billion. Cash and short-term financial assets reached KRW 630.8 billion at the end of the first quarter of 2026, according to press reporting.

Relative to earnings, the company has accumulated substantial internal cash rather than distributing a large share of profit. When interpreting earnings-based multiples, it helps to pair quarterly volatility with the annual trend.

Comparisons with the past trading band depend on the price level at each point in time and need to be checked at that point.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Rapid expansion of overseas sales

The overseas share of third-quarter 2026 sales expanded to about 48%. Cosmetics exports rose 92% year on year to KRW 42.1 billion, and medical device exports rose 53% to about KRW 30 billion.

Rejuran exceeded initial plans in France, its first year in Europe, and held overseas approvals in 52 countries as of an August 2026 report.

Higher margins and lower cost ratio

The operating margin rose from 33.8% in 2022 to 40.0% in 2025. Cost of sales as a share of revenue fell from 28.2% in 2024 to 23.3% in 2025 and reached 22.7% in the first quarter of 2026, according to Deal Bio reporting. Operating cash flow of KRW 183.2 billion in 2025 set another record high.

Financial capacity built without borrowing

Total equity at the end of 2025 was KRW 723.9 billion, and the debt ratio was 44.2%. According to Deal Bio reporting, the company operates without rights offerings or short- and long-term borrowing, and cash and short-term financial assets totaled KRW 630.8 billion at the end of the first quarter of 2026.

09

Bear factors

Slowing quarterly profit

Third-quarter 2026 revenue fell 4.0% from the prior quarter, and operating profit fell 5.8%. Net profit attributable to controlling shareholders dropped 47.1% from the prior quarter to KRW 30 billion.

Operating profit also fell 16.1% quarter on quarter in the fourth quarter of 2025, so quarterly profit has moved up and down.

Rising selling and administrative costs

Selling, general and administrative expenses rose 57.2% from KRW 125.2 billion in 2024 to KRW 196.8 billion in 2025, according to Deal Bio reporting. The SG&A ratio rose to 36.7% in 2025 and 38.1% in the first quarter of 2026. The breakdown of the SG&A increase is a point to check in the annual business report.

Concentration on Rejuran and a few channels

The two segments of medical devices and cosmetics together accounted for 83.1% of sales in 2025, according to Deal Bio reporting. As the overseas share rises, exposure to specific distribution channels and country-level approval or policy changes also grows.

Cosmetics results depend heavily on sales flows through a small number of channels such as Olive Young, Sephora and Amazon.

10

Risk factors

Regulatory and approval risk

Rejuran's overseas growth depends on product approvals and medical device rules in each country. Entry into new South American and Middle Eastern markets requires local approvals and distribution partners. Approval delays or regulatory changes could alter the pace of export growth.

Currency and distribution channel risk

With overseas sales at about 48% of third-quarter 2026 revenue, the company has substantial exposure to foreign currency and exchange rate movements. Cosmetics exports depend on online and offline channels in the United States and Southeast Asia, which makes them sensitive to platform or distribution policy changes. Changes in channel contract terms could directly affect sales volume.

Cost and quarterly volatility risk

Selling, general and administrative expenses rose 57.2% in 2025, which kept pace with sales growth.

Quarterly operating profit moved from KRW 51.9 billion in the fourth quarter of 2025 to KRW 66.5 billion in the second quarter of 2026 and KRW 62.6 billion in the third quarter, while net profit attributable to controlling shareholders swung more widely. Even at high margins, quarterly swings can reduce confidence in earnings estimates.

11

What to watch next

  1. End of December 2026

    Results of the fourth-quarter push into South America (Mexico, Argentina and Chile) and the Middle East (centered on the UAE), and whether the company meets its stated goal of a record quarterly result. The plan was announced on November 6, 2026.

  2. Early 2027

    Timing of fourth-quarter 2026 results. Check how revenue and operating profit compare with the fourth quarter of 2025 (KRW 143.3 billion in revenue and KRW 51.9 billion in operating profit) and the third quarter of 2026, and whether the operating margin holds near the third-quarter level of 36.5%.

  3. End of March 2027

    Filing of the 2026 annual business report. Review the annual revenue mix, the breakdown of SG&A, and non-operating and tax items to see whether they explain why operating profit rose in the third quarter while net profit attributable to controlling shareholders fell.

  4. First half of 2027

    Whether the French local business base and the U.S. CG USA production facility help sustain the export share. The company outlined these plans in August 2026.

12

Overall view

PharmaResearch is a company whose export sales of medical devices and cosmetics, led by Rejuran, have lifted results. On the basis of disclosed figures, 2025 revenue was KRW 536.3 billion, up 53.2%, and the operating margin reached 40.0%.

In the third quarter of 2026 the company recorded revenue of KRW 171.5 billion and operating profit of KRW 62.6 billion, and the export share widened to about 48%. In the same quarter, operating profit rose only 1.2% year on year, and net profit attributable to controlling shareholders fell 38.8%.

Selling, general and administrative expenses rose 57.2% in 2025, leaving cost flow as a key variable. Strengths include expanding overseas approvals and financial capacity, while weaknesses include slowing quarterly profit, SG&A pressure and channel concentration.

The next checkpoints are fourth-quarter 2026 results, progress in South America and the Middle East, and the cost structure disclosed in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. pharmaresearch.com
  2. m.news.nate.com
  3. thebionews.net
  4. m.news.nate.com
  5. sedaily.com
  6. m.news.nate.com
  7. m.news.nate.com
  8. sentv.co.kr
  9. news.mtn.co.kr
  10. bosa.co.kr
  11. insight.co.kr
  12. todaymild.com
  13. etoday.co.kr
  14. msn.com
  15. shinailbo.co.kr
  16. vegannews.co.kr
  17. medicopharma.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis